Investors / Belgium / Bioqube Ventures
Bioqube Ventures
Venture capital · Brussels, Belgium · Europe
Bioqube Ventures is a life sciences venture capital firm that invests in therapeutics companies, combining venture creation, early-stage company building and selective clinical co-investment. Founded in 2015, it has backed over 20 biotech companies and has offices in Belgium and the United States.
Invests inHealthcare & Biotech
In its own wordstherapeuticsbiotechlife sciencesventure creationclinical development
Your fit with Bioqube Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsBioqube Ventures lists 5 checked portfolio companies on its own site and is named in 1 funding round, 1 of them as lead. Its most frequent entry is Series B, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 50% of its companies are based in United States. It invests most often alongside AdBio partners, Advent Life Sciences and Beiersdorf Venture Capital.
Counts come from funding rounds that name Bioqube Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundBioqube Ventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 100% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 4th | 5 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| AdBio partners | 1 |
| Advent Life Sciences | 1 |
| Beiersdorf Venture Capital | 1 |
| BioGeneration Ventures | 1 |
| BioRock Ventures | 1 |
| Brandon BioCatalyst | 1 |
| Brandon Capital | 1 |
| Canaan | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers5100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Bioqube Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
as stated on its siteRecent portfolio activity
when companies last raised with Bioqube Ventures| Date | Company | Stage |
|---|---|---|
| 26 Jan 2026 | Series B Led |
Round details for Bioqube Ventures
Amounts, full round histories and every co-investor in Bioqube Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
5 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Actithera develops innovative radiotherapeutics by linking radioactive isotopes to carefully designed molecules to fight cancer. | Healthcare & Biotech | Portfolio page | ||
| CatalYm is developing a safe and efficacious immune therapy for solid tumors. | Healthcare & Biotech | Portfolio page | ||
| Primmune is a clinical-stage biotechnology company focused on developing systemic cancer immunotherapies that activate the immune system in a precise and controlled manner. | Healthcare & Biotech | Jan 2026Series B | Funding round | |
| S-Biomedic pioneers microbiome-based skincare for all by harnessing the full potential of the skin microbiome | Healthcare & Biotech | Portfolio page | ||
| Tridek-One develops first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- bioqubeventures.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 26 Jan 2026
- Companies checked
- 5
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Bioqube Ventures' profile as data
Pull Bioqube Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/bioqubeventures.com
# also
GET /v1/firms/bioqubeventures.com/portfolio
GET /v1/firms/bioqubeventures.com/coinvestors
GET /v1/firms/bioqubeventures.com/news